Dignitana AB Publishes Q2 2021 Interim Report
US treatment growth drives 23 percent increase in net revenue
Financial highlights Q2 2021
- Net sales amounted to 14 MSEK (11,4), an increase of 23 percent over the same period 2020.
- Operating result amounted to -9,4 MSEK (-9,0)
- Net result after financial items amounted to -9,7MSEK (-9,5)
- Earnings per share were -0,15 SEK (-0,17)
- Cash Balance amounted to 36,3 MSEK (7,5)
- Average Daily Treatment Revenue (ADTR)* was 163 TSEK (109), an increase of 49 percent over the same period in 2020.
Financial highlights January – June 2021
- Net sales amounted to 27,2 MSEK (22,8), an increase of 19 percent over the same period 2020.
- Operating result amounted to -16,5 MSEK (-21,5)
- Net result after financial items amounted to -17,3 MSEK (-22,3)
- Earnings per share were -0,28 SEK (-0,40)
- Cash Balance amounted to 36,3 MSEK (7,5)
- Average Daily Treatment Revenue (ADTR)* was 146 TSEK (106), an increase of 38 percent over the same period in 2020.
Significant events during the period
- The Annual General Meeting was held in Lund in May and resolved all proposed items in accordance with the announced proposals.
- In April Dignitana published the Annual Report for 2020.
Business highlights during the period
-
Dignitana-backed insurance legislation in Texas did not come to a full vote prior to the close of the session in May.
Business highlights after the period
- In June Dignitana launched new initiatives to support reimbursement and market access in the US.
- Dignitana signed distributor B&Co Group to support Benelux Growth in July.
- The Board of Directors has appointed The Chairman of the Board Klas Arildsson to the role of a working Chairman supporting growth from an operational point of view. He will focus on Quality and Regulatory Affairs and operational efficiency.
Key Figures
|
Dignitana Group |
Q2 2021 |
Q2 2020 |
Q1-Q2 2021 | Q1-Q2 2020 | Full year 2020 |
| Net revenues, TSEK | 14 038 | 11 423 | 27 203 | 22 816 | 46 629 |
| Total revenues, TSEK | 17 174 | 11 876 | 31 331 | 24 353 | 49 956 |
| Net profit after financial items, TSEK | -9 660 | -9 528 | -17 324 | -22 283 | -52 963 |
| Cash and bank balances, TSEK | 36 333 | 7 484 | 36 333 | 7 484 | 78 770 |
| Earnings per share before and after dilution, SEK | -0,15 | -0,17 | -0,28 | -0,40 | -0,96 |
| Average Daily Treatment Revenue*, TSEK | 163 | 109 | 146 | 106 | 120 |
* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 19-08-2021 08:00 CET.
For More Information Contact
Melissa Bourestom, VP Corporate Communications, melissa.bourestom@dignitana.com +1 469-518-5031
About Dignitana
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB +46 8 121 576 90, certifiedadviser@redeye.se. Learn more at www.dignitana.se or www.dignicap.com.
Tags: